October 9, 2013
…of Medicine, says a gene mutation that causes a rare but devastating neurological disorder known as Lesch-Nyhan syndrome appears to offer clues to the developmental and neuronal defects found in other, diverse neurological disorders like Alzheimer’s, Parkinson’s and Huntington’s diseases.
August 8, 2018
…appendiceal tumors — the largest such study of this disease to date — to compare mutations present in both cancer types.
October 12, 2016
…underappreciated role in promoting the heritable form of Alzheimer’s disease (AD), but also one that might be remedied with existing therapeutic enzyme inhibitors.
September 8, 2015
Using “mini-brains” built with induced pluripotent stem cells derived from patients with a rare, but devastating, neurological disorder, researchers at University of California, San Diego School of Medicine say they have identified a drug candidate that appears to “rescue” dysfunctional cells by suppressing a critical genetic alteration.
March 14, 2017
An international research team, led by scientists at University of California San Diego School of Medicine, has created the first cellular model of anorexia nervosa (AN), reprogramming induced pluripotent stem cells (iPSCs) derived from adolescent females with the eating disorder.
July 12, 2021
UC San Diego researchers discovered that immunotoxins targeting the protein mesothelin prevent liver cells from producing collagen, a precursor to fibrosis and cirrhosis, in mouse models of human disease.
November 10, 2022
An international symposium November 17-18, 2022 at UC San Diego will discuss current clinical trials using gene therapy, here and abroad.
May 18, 2020
A team at the University of California San Diego has developed a wearable, non invasive Vitamin C sensor that could provide a new, highly personalized option for users to track their daily nutritional intake and dietary adherence. The study was published in the May 18, 2020 issue of ACS Sensors.
May 18, 2023
Across disciplines and specialties, from cells to systems, artificial intelligence is on its way to altering how we understand and treat disease.
August 7, 2019
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
